Description
Developer of immunological reagents. The company develops monoclonal antibodies for the treatment of cancer, brain damage and tumors.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Merger/Acquisition | 31-May-2006 | Completed | Generating Revenue | |||
2. Angel (individual) | 01-Jan-2001 | Completed | Generating Revenue | |||
1. Early Stage VC | Completed | Startup |
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20040176577-A1 | Monoclonal antibody for classifiying squamous cell carcinoma antigen (scca) species and diagnosis of cell proliferative disorders | Abandoned | 10-Sep-2002 | 000000000 | |
US-20080057520-A1 | Monoclonal antibody for detecting squamous cell carcinoma antigen (scca); diagnostic indicator for cancer screening; immunodiagnostics | Abandoned | 10-Sep-2002 | 000000000 | |
US-20050089534-A1 | Immunogenic rafts, lipid enriched membrane domains, and their use in cancer therapy;tumor protein(-s) and/or glycosphingolipid(-s); vaccine; immunotherapy | Abandoned | 14-Aug-2002 | 00000000000 | |
US-6555327-B1 | Immunoas say for specific determination of total calcium binding protein s100 or the different isoforms of s100 in serum, plasma, cerebrospinal or other body fluids | Expired - Lifetime | 28-Aug-1998 | 000000000 | |
DE-69931054-T2 | Monoclonal antibodies against s100 | Expired - Lifetime | 28-Aug-1998 | C07K16/18 |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Börje Karlsson | Co-Founder | ||
Leif Lindholm | Co-Founder |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Industrifonden | Venture Capital | Minority | 000 0000 | 000000 0 | |
Líftæknisjóðurinn MP BIO hf | Venture Capital | Minority | 000 0000 | 000000 0 |